4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609275171/en/
(Graphic: Business Wire)
Lasare Phase I trial is a multi-center, randomized, double-blinded, placebo-controlled involving 34 patients across three sites in Belgium.
The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004).
The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed and simulated Cmax values, also indicated lower systemic exposure than reported for subcutaneous liraglutide injection from the approved product, Victoza®, affirming the company’s plan to pursue a 505(b)(2) regulatory pathway in the US for 4P004.
Pr. Francis Berenbaum, Co-founder and Chief Medical Officer of 4Moving Biotech, declared: "The Success of the Phase 1 study of 4P004 underscores the quality of our advancements in the quest for therapeutic solutions for patients suffering from knee osteoarthritis. Furthermore, with the established safety and tolerability profiles, we are progressing confidently to the next stage of clinical development with 4P004."
As for ultimate goal, 4Moving Biotech’s strategy intends to secure accelerated approvals in the US and EU for early market entry at the end of the planned Phase 2b efficacy and safety trial. Toward this goal, the company recently received constructive pre-IND guidance from the FDA, translating 4Moving Biotech’s planned potential accelerated approval driven strategy into a highly differentiated clinical program catalyzed by a unique combination of reasonably likely surrogate endpoints, supported by sophisticated in silico AI-based prognostic modelling.
Revital Rattenbach, Chairwoman of 4Moving Biotech, stated: "Beyond the positive results from our phase I clinical study on knee osteoarthritis, the FDA's positive echoing has built a tremendous momentum for our accelerated strategy to the market, with hopes to bring to OA patients the first therapy being able to modify the natural course of the disease."
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
About Lasare
This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program. The funding agencies supporting this work are (in alphabetical order of participating countries): France: BPI France ; Germany: Project Management Agency (DLR), which acts on behalf of the Federal Ministry of Education and Research (BMBF); The Netherlands: Netherlands Enterprise Agency (RVO); Switzerland: Innosuisse (the Swiss Innovation Agency).
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609275171/en/
Contact information
Press :
Emmanuel Dadje
Communication Manager
+33 6 30 06 12 13
emmanuel.dadje@4P-Pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group’s AI Health Service AQ Upgrades PC Platform with DeepSearch for Evidence-Based Clinical Decision Support21.1.2026 05:12:00 EET | Press release
Ant Group today announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capability designed to support evidence-based clinical decision-making. The service is available free of charge to clinicians and medical students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120591991/en/ AQ’s PC platform provides medical professionals with two core capabilities: Health Q&A and DeepSearch. It supports medical literature search, clinical practice, and research, helping reduce clinicians’ day-to-day workload while improving access to high-quality medical information. To ensure accuracy and reliability, AQ rigorously curates its sources based on recognized levels of evidence. The platform integrates more than 36 million high-quality Chinese and international medical publications, making its clinical decision support closely aligned with real-world practice. Deep
NIKE, Inc. Announces New Geography Leadership Appointments20.1.2026 23:15:00 EET | Press release
NIKE, Inc. (NYSE: NKE) today shared the following note with teammates regarding changes to its Senior Leadership Team: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120575539/en/ César Garcia, VP/GM Nike Europe, Middle East and Africa (EMEA) To: Lst-Global From: EHill Subject: Leadership Announcements Team, In recent months, the Senior Leadership Team has benefited from having our Geography VP/GMs at the table helping us move faster and bringing us closer to athletes* in both countries and marketplaces around the world. As we continue to drive our Win Now actions and stand up our Sport Offense, I’d like to share several important leadership changes across three of our Geo VP/GM roles. EMEA Carl Grebert, a true legend on our team, has decided to retire after nearly 30 years of service and leadership across global, country and geography roles across the company. Carl shared his thinking with me some time ago, and I’m deepl
Xsolla Expands Payment Coverage in Portugal With MB Way, a Leading Mobile Wallet Trusted by 6 Million Customers, to Unlock New Growth Opportunities for Game Developers20.1.2026 17:41:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced the expansion of its payments solution in Portugal with the addition of MB Way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938007/en/ Graphic: Xsolla Portugal is a leader in digital transformation, with nearly 90% of its population online, high smartphone usage, and a strong adoption of mobile banking. Trusted by 6 million people, connected to 11 million cards, supported by 28 banks, and driving 496 million transactions in 2024, MB Way provides 95% market coverage, allowing most bank customers to use the service. MB Way is the leading mobile wallet in Portugal, with an estimated market share of 34%-45% of all e-commerce transactions locally. By adding MB Way as a payment method to its portfolio, Xsolla continues to deliver the fast and flexible payment experience Portuguese players expect. Key
Andersen Consulting Adds Collaborating Firm Africa International Advisors20.1.2026 16:30:00 EET | Press release
Andersen Consulting extends its strategy and business transformation capabilities in Africa through a Collaboration Agreement with Africa International Advisors (AIA), a Johannesburg-based firm focusing on enhancing business competitiveness through sector specific insights, innovation and advisory services. Founded in 2002, AIA is a pan-African management consulting firm that delivers strategy-led advisory services with a focus on digital transformation and AI-driven business outcomes. The firm advises clients across sectors including energy and resources, oil and gas, infrastructure, trade and logistics, financial services, banking, and telecom. AIA’s strategic perspective, local credibility, and market access enable it to design and implement solutions that align people, processes, and technology to drive meaningful change. “From the beginning, our mission has been to drive progress through an Africa-centered lens, grounded in the realities and ambitions of the continent,” said Hasna
Balena Secures Strategic Growth Investment to Accelerate Edge AI and IoT Fleet Management20.1.2026 16:14:00 EET | Press release
Balena, the leading platform for deploying, managing, and scaling fleets of edge computing and AI devices, today announced a strategic growth investment from LoneTree Capital (“LoneTree”), a New York-based growth capital firm. The partnership will accelerate Balena’s product innovation with a focus on Edge AI workloads and security features to meet evolving compliance needs, while expanding resources for customer success and global fleet support. Founded in 2011, Balena enables customers to leverage the ever-increasing power of technology to solve real-world problems by providing software to manage the full lifecycle of edge computing devices. The platform abstracts away infrastructure complexity, handling critical tasks like secure Over-The-Air (OTA) updates so engineering teams can focus on their core product. As a truly hardware-agnostic solution, Balena empowers customers to deploy their applications, including intensive Edge AI workloads, on the devices of their choice, avoiding v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom